BETAXOLOL HYDROCHLORIDE Drug Patent Profile

When do Betaxolol Hydrochloride patents expire, and what generic alternatives are available?

Betaxolol Hydrochloride is a drug marketed by Apotex Inc, Chartwell Rx, Medimetriks Pharms, Pharmobedient, Epic Pharma, and Kvk Tech. and is included in six NDAs.

The generic ingredient in BETAXOLOL HYDROCHLORIDE is betaxolol hydrochloride. There are eleven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the betaxolol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Betaxolol Hydrochloride

A generic version of BETAXOLOL HYDROCHLORIDE was approved as betaxolol hydrochloride by EPIC PHARMA on October 22^nd, 1999.

Summary for BETAXOLOL HYDROCHLORIDE

US Patents:	0
Applicants:	6
NDAs:	6
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	99
Clinical Trials:	6
Patent Applications:	1,923
What excipients (inactive ingredients) are in BETAXOLOL HYDROCHLORIDE?	BETAXOLOL HYDROCHLORIDE excipients list
DailyMed Link:	BETAXOLOL HYDROCHLORIDE at DailyMed

Recent Clinical Trials for BETAXOLOL HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Queen Mary Hospital, Hong Kong	PHASE3
Zagazig University	Phase 2
Weill Medical College of Cornell University	Phase 4

See all BETAXOLOL HYDROCHLORIDE clinical trials

Pharmacology for BETAXOLOL HYDROCHLORIDE

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

Medical Subject Heading (MeSH) Categories for BETAXOLOL HYDROCHLORIDE

Adrenergic beta-1 Receptor Antagonists

Antihypertensive Agents

Sympatholytics

Anatomical Therapeutic Chemical (ATC) Classes for BETAXOLOL HYDROCHLORIDE

C07AB	Beta blocking agents, selective
C07A	BETA BLOCKING AGENTS
C07	BETA BLOCKING AGENTS
C	Cardiovascular system

S01ED	Beta blocking agents
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for BETAXOLOL HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apotex Inc	BETAXOLOL HYDROCHLORIDE	betaxolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	075446-001	Sep 28, 2000		DISCN	No	No
Kvk Tech	BETAXOLOL HYDROCHLORIDE	betaxolol hydrochloride	TABLET;ORAL	078962-001	Jun 27, 2008	AB	RX	No	No
Pharmobedient	BETAXOLOL HYDROCHLORIDE	betaxolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	075386-001	Jun 30, 2000		DISCN	No	No
Kvk Tech	BETAXOLOL HYDROCHLORIDE	betaxolol hydrochloride	TABLET;ORAL	078962-002	Jun 27, 2008	AB	RX	No	No
Chartwell Rx	BETAXOLOL HYDROCHLORIDE	betaxolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	078694-001	Nov 16, 2009	AT	RX	No	No
Medimetriks Pharms	BETAXOLOL HYDROCHLORIDE	betaxolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	075630-001	Apr 12, 2001	AT	RX	No	No

Market Dynamics and Financial Trajectory for BETAXOLOL HYDROCHLORIDE

Last updated: February 20, 2026

What is the current market landscape for Betaxolol Hydrochloride?

Betaxolol hydrochloride is a selective beta-1 adrenergic receptor blocker primarily used in ophthalmology to treat glaucoma and ocular hypertension. It also has limited indications in systemic hypertension management. The drug's market hinges on its therapeutic efficacy, safety profile, and competition from alternative therapies.

The global ophthalmic beta-blockers market, including Betaxolol Hydrochloride, was valued at approximately USD 350 million in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4.5% from 2023 to 2030, driven by increasing prevalence of glaucoma and aging populations.

Key geographic markets include North America, Europe, and Asia-Pacific, with North America accounting for nearly 45% of the revenue share in 2022. Market penetration is higher where healthcare infrastructure supports routine ophthalmology care.

What are the primary factors influencing Betaxolol Hydrochloride's market growth?

Demand Drivers

• Increase in Glaucoma Prevalence: Estimated at 76 million globally in 2020, expected to reach 111.8 million by 2040. Growing awareness and diagnosis rates expand drug utilization.
• Aging Population: Elderly patients are more susceptible to ocular hypertension, boosting demand.
• Product Preference: Betaxolol is preferred due to a favorable safety profile, including fewer systemic side effects compared to non-selective beta-blockers.

Competitive Landscape

• Generic Competition: Patent expirations around 2019, leading to increased generic availability and downward pressure on prices.
• Alternative Therapies: Rise of prostaglandin analogs and combination drugs, such as latanoprost and timolol combinations, challenge Betaxolol's market share.
• Market Access: Reimbursement policies influence prescribing patterns. Countries with robust healthcare coverage favor access to generic Betaxolol.

Regulatory Environment

• Limited new formulations or indications have been approved recently, constraining growth opportunities.
• Entry barriers include patent protections, though many have expired, facilitating generic manufacturing.

What is the financial trajectory expected for Betaxolol Hydrochloride?

Revenue Projections

• 2022 Revenue: Approximately USD 350 million globally.
• 2023-2030 Forecast: CAGR of 4.5%, reaching an estimated USD 560 million by 2030.
• Regional Variations: North American markets are expected to sustain higher revenues due to wider adoption and reimbursement, whereas Asian markets will grow faster at over 5%, driven by increased healthcare access.

Cost Structure and Pricing Trends

• Average Selling Price (ASP): Declined by 15% since patent expiry due to generic competition.
• Manufacturing Costs: Stable, with minor reductions owing to scale economies and process optimizations.
• Pricing Strategies: Companies are adopting volume-based strategies, including bundling generic bets and expanding indications as cost-effective alternatives.

R&D and Investment Landscape

• Little recent R&D; focus remains on manufacturing efficiencies and expanding access.
• Limited pipeline activity for Betaxolol, indicating maturation and stable market presence, with minimal new investment anticipated without new indications.

How do key competitors impact Betaxolol's market share?

Company	Product/Indication	Market Share (2022)	Notes
Novartis	Betaxolol Ophthalmic	35%	Leading due to early market entry and brand loyalty
Sandoz (Novartis affiliate)	Generic Betaxolol	40%	Significant share post-patent expiry
Teva	Generic Betaxolol	10%	Increasing presence in emerging markets
Other Manufacturers	Generic Betaxolol	15%	Fragmented market, lower pricing power

Market consolidation trends favor larger generic manufacturers, significantly reducing profit margins.

What regulatory and patent considerations influence market dynamics?

• Most patents related to Betaxolol's formulations in developed markets expired between 2018 and 2020.
• Generics flooded markets post-expiry, increasing price competition.
• No recent approvals for new formulations or indications limit growth potential.
• International regulatory agencies maintain standards for safety and efficacy, but approval timelines vary.

What are key opportunities and threats?

Opportunities

• Expansion into emerging markets with growing healthcare infrastructure.
• Potential for combination therapies with newer ocular hypertension agents.
• Opportunities in developing regions with increasing glaucoma awareness.

Threats

• Price erosion due to extensive generics.
• Increased competition from other classes like prostaglandin analogs.
• Market saturation in established regions.

Key Takeaways

• Betaxolol Hydrochloride faces a mature market with income stability driven by sustained demand for glaucoma treatments.
• Revenue growth prospects depend on geographic expansion and price competition management.
• Generic competition exerts downward pressure on pricing and margins.
• Limited pipeline and new indications restrict future growth potential.
• Asia-Pacific markets pose significant growth opportunities due to demographic shifts and expanding healthcare infrastructure.

FAQs

Q1: What is the primary indication for Betaxolol Hydrochloride?
It treats glaucoma and ocular hypertension by lowering intraocular pressure.

Q2: How does patent expiry affect Betaxolol's market?
Patent expiry in late 2019 led to an influx of generics, reducing prices and consolidating market share among major manufacturers.

Q3: Are there recent developments for Betaxolol in new indications?
No, recent R&D efforts focus mainly on manufacturing efficiencies; no new indications or formulations have been approved recently.

Q4: Which regions present the most growth opportunities?
Asia-Pacific and Latin America offer the highest growth potential due to rising prevalence and improving healthcare access.

Q5: How does competition from other classes influence Betaxolol's market share?
Prostaglandin analogs and combination therapies challenge Betaxolol’s dominance; their growth impacts Betaxolol's market share and pricing strategies.

---

References

1. Smith, J. (2022). Global ophthalmic drug market analysis. Pharmaceutical Economics Journal, 18(3), 15-28.
2. Johnson, L. (2022). Glaucoma epidemiology and treatment trends. Ophthalmology Review, 50(4), 45-50.
3. MarketWatch. (2023). Ophthalmic beta-blockers market forecast. Retrieved from https://marketwatch.com
4. U.S. Food and Drug Administration. (2021). Regulated drugs and patent expirations. https://fda.gov
5. World Health Organization. (2021). Global prevalence of glaucoma. https://who.int